Wegovy Pill: Oral Semaglutide 25 mg Evidence and Approval

What the Wegovy Pill Is

The Wegovy pill is an oral formulation of semaglutide approved by the Food and Drug Administration (FDA) at a 25 mg daily maintenance dose for chronic weight management and cardiovascular risk reduction in adults. Novo Nordisk announcement records dated 22 December 2025 confirm the regulatory clearance, describing it as the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management. In that same announcement, the manufacturer stated that it expected to launch the Wegovy pill in the United States in early January 2026.

The medication carries two approved indications in adults when used alongside a reduced-calorie diet and increased physical activity. First, it is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight who have at least one weight-related comorbid condition. Second, it is approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.

Treatment involves taking one tablet daily in the morning on an empty stomach with up to 4 ounces of plain water. Dosing follows a 90-day escalation ladder that begins at 1.5 mg daily before advancing through 4 mg and 9 mg, reaching the 25 mg maintenance dose on day 91. In its 64-week primary clinical trial, the 25 mg tablet delivered a mean body weight change of −13.6% compared with −2.4% on placebo across all randomized patients, and 16.6% among participants who adhered to treatment. The Wegovy pill is not the same medication as Rybelsus or Ozempic tablets, which are approved solely for type 2 diabetes. A unified prescribing information document revised in June 2026 covers both the oral tablet and the subcutaneous pen formulations.

Tablet and Injection Specifications at a Glance

The Wegovy tablet and the subcutaneous pen share the active ingredient semaglutide but differ in dosing cadence, escalation schedules, and approved clinical indications. Both formulations deliver semaglutide for chronic weight management and cardiovascular risk reduction in adults with obesity, or overweight plus at least one weight-related comorbid condition.

The comparison table below details the specifications of both formulations as established in the unified prescribing information. Readers evaluating which format fits their daily schedule can review our in-depth analysis of the Wegovy pill vs injection for a complete clinical breakdown.

Who the Label Covers

The FDA-approved prescribing information specifies two clinical indications for Wegovy tablets in adult patients alongside a reduced-calorie diet and increased physical activity. First, the medication is indicated to reduce excess body weight and maintain long-term weight reduction in adults with obesity, or in adults with overweight who have at least one weight-related comorbid condition. Second, it is approved to reduce the risk of major adverse cardiovascular events, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight.

An important regulatory boundary separates the oral tablets from the subcutaneous injection. While Wegovy injection is approved for paediatric patients aged 12 and older with obesity, and holds accelerated approval for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, Wegovy tablets carry neither of these indications. The tablets are approved strictly for adult patients.

The label also specifies that using Wegovy tablets in combination with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. The prescribing information rules out treatment for several specific patient groups through absolute contraindications. Wegovy tablets are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), in individuals with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in anyone with a prior serious hypersensitivity reaction to semaglutide or any tablet excipient.

These label criteria define the clinical boundaries established by regulatory authorities. A licensed healthcare provider must evaluate your medical history, current diagnoses, and concurrent therapies to determine whether oral semaglutide is appropriate for your individual situation.

The Ninety-Day Dose Ladder

Reaching the approved 25 mg maintenance dose of the Wegovy pill requires a structured 90-day titration protocol across three preliminary strengths. Patients do not begin treatment at 25 mg; instead, the label establishes three 30-day preliminary steps before reaching the maintenance dose. The approved maintenance dose of 25 mg daily begins on day 91.

If a patient does not tolerate a specific step during escalation, the prescribing information directs the clinician to consider delaying dosage escalation. Administration requires strict adherence to morning timing and fluid limits. The label instructs patients to take one tablet orally once daily on an empty stomach in the morning with up to 4 ounces of plain water, avoiding any other liquids.

Tablets must be swallowed whole, and patients must never split, crush, chew, or dissolve them. Patients must wait at least 30 minutes after swallowing the tablet before consuming food, beverages, or other oral medications. Never take more than one tablet per day; if a dose is missed, the label directs patients to skip the missed dose and take the next dose the following day as scheduled.

The oral tablets and the subcutaneous injection are not interchangeable on a milligram-for-milligram basis. For patients transitioning between delivery formats, the label outlines clear conversion steps. A patient receiving the 2.4 mg once-weekly injection may start the 25 mg tablet one week after their last injection, while a patient on the 25 mg tablet may start the 2.4 mg injection the day after their final tablet.

In adults with type 2 diabetes who experience an inadequate therapeutic response to the oral tablets, the prescribing information directs clinicians to consider alternative therapies, including switching to Wegovy injection. Practical daily routines for managing these morning steps are detailed in our guide on how to take the Wegovy pill.

What the Trial Measured

Efficacy data for the Wegovy pill come from Study 7 in the FDA prescribing information, registered as clinical trial NCT05564117 and designated by Novo Nordisk as OASIS 4. This 64-week randomized, double-blind, placebo-controlled trial evaluated 307 adults with obesity, or overweight with weight-related comorbidities. Investigators randomized participants in a 2:1 ratio, assigning 205 adults to once-daily oral semaglutide escalated to 25 mg over 12 weeks, followed by a 52-week maintenance period, and 102 adults to a matching placebo.

The trial data generated two different headline efficacy figures, representing two distinct statistical frameworks. In the primary treatment-policy estimand reported in the FDA prescribing information, participants assigned to the 25 mg tablet achieved a mean body weight change of −13.6% at week 64, compared with −2.4% in the placebo group. This represents a statistically significant placebo-adjusted difference of −11.2% (95% confidence interval −13.6 to −8.8, p<0.0001).

The treatment-policy analysis evaluates all randomized participants across the full 64 weeks, regardless of whether they paused doses, discontinued early, or initiated other therapies. By contrast, Novo Nordisk's regulatory announcement reported a 16.6% mean weight reduction derived from the trial-product estimand. That second analysis estimates the weight reduction achieved when participants adhered strictly to the assigned treatment regimen throughout the entire study period.

Novo Nordisk also reported that one in three people in OASIS 4 achieved 20% or greater total weight loss. Both figures reflect verified trial data: 13.6% measures the outcome across an entire assigned cohort including non-completers, while 16.6% measures the outcome among patients who took the tablet as directed. Discontinuations due to adverse reactions occurred in 6.8% of patients receiving the 25 mg tablet compared with 5.9% of patients receiving placebo.

In its public announcements, Novo Nordisk stated that the weight loss achieved with the Wegovy pill is similar to that of injectable Wegovy 2.4 mg. This statement represents the manufacturer's own characterization of a cross-trial comparison rather than a finding from a direct head-to-head trial. No head-to-head randomized trial comparing the 25 mg tablet directly against the 2.4 mg injection has been conducted. Beyond OASIS 4, the regulatory approval rests on data from the SELECT cardiovascular outcomes trial, alongside supportive data from the STEP clinical trial programme and PIONEER PLUS.

Three Oral Semaglutide Products, Not One

Novo Nordisk manufactures three distinct oral semaglutide products with overlapping numerical strengths but separate FDA-approved clinical indications. A single prescribing-information document updated on DailyMed on 30 January 2026 covers both Rybelsus and Ozempic tablets under the title OZEMPIC- oral semaglutide tablet RYBELSUS- oral semaglutide tablet. Both of those products are indicated solely for improving glycemic control in adults with type 2 diabetes and reducing cardiovascular risk in adults with type 2 diabetes who have high cardiovascular risk. Neither product is approved for weight management.

Rybelsus is formulated in strengths of 3 mg, 7 mg, and 14 mg, where the 3 mg starting dose is not effective for glycemic control and serves only for initial titration. Ozempic tablets are formulated in strengths of 1.5 mg, 4 mg, and 9 mg, where the 1.5 mg starting dose similarly serves only for initial titration. Rybelsus and Ozempic tablets are not substitutable on a milligram-for-milligram basis; instead, the label establishes that 7 mg of Rybelsus corresponds to 4 mg of Ozempic tablets, while 14 mg of Rybelsus corresponds to 9 mg of Ozempic tablets.

The Wegovy pill shares the exact numerical titration strengths of 1.5 mg, 4 mg, and 9 mg with Ozempic tablets. However, the Wegovy pill alone escalates to the higher 25 mg maintenance dose, and the Wegovy pill alone carries FDA approval for chronic weight management. The products are distinct pharmaceutical preparations that are not interchangeable, and the prescribing information warns that using multiple semaglutide-containing products together is not recommended.

All three oral semaglutide products share the same strict administration requirements because of the pharmacology of oral peptide delivery. Oral semaglutide tablets exhibit an absolute bioavailability of roughly 1% to 2%, compared with approximately 89% for subcutaneous injection. Peak concentration occurs roughly 1 hour after an oral dose compared with 1 to 3 days after injection, which is the pharmacological reason the empty-stomach and 30-minute rules exist.

To review clinical differences between oral formulations, see our dedicated guide on the Wegovy pill vs Rybelsus. For a step-by-step breakdown of the morning routine, consult our instructions on how to take the Wegovy pill.

Cost, Coverage and What the Label Warns About

Self-pay pricing for the Wegovy pill starts at $149 per month for the initial titration strength and reaches $299 per month for the 25 mg maintenance dose at NovoCare Pharmacy. Specifically, out-of-pocket prices for a 30-day bottle of 30 tablets are listed at $149 per month for 1.5 mg, $199 per month for 4 mg, and $299 per month for 9 mg and 25 mg. An introductory savings offer advertises paying as little as $25 with a maximum savings of $100 per month for up to 3 months, with government beneficiaries excluded and eligibility restrictions applying.

By comparison, NovoCare lists self-pay prices for the Wegovy injection pen at $199 per month for 0.25 mg and 0.5 mg for new patients for two monthly fills through 31 December 2026, followed by $349 per month for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg and $399 per month for the 7.2 mg pen. The NovoCare page carries no effective date and notes that programs may change or cancel at any time, so readers should verify current pricing directly at NovoCare Pharmacy. A complete analysis of out-of-pocket expenses is provided in our Wegovy pill cost guide.

For Medicare beneficiaries, the Centers for Medicare & Medicaid Services (CMS) operates a demonstration called the Medicare GLP-1 Bridge between 1 July 2026 and 31 December 2027. Under this demonstration, eligible beneficiaries have a $50 copay for select weight-loss medications, including Foundayo, Wegovy injection, Wegovy tablets, and Zepbound in the KwikPen formulation only. This $50 copay sits outside the standard Part D benefit: the Part D deductible does not apply, the copay does not count toward true out-of-pocket costs, and no low-income subsidy is provided.

Because CMS does not publish specific beneficiary qualification rules on its announcement page, individuals must visit Medicare.gov/glp1bridge and speak with their physician to confirm eligibility. Outside this demonstration, commercial and Medicare coverage depends entirely on individual plan formularies. Like the injectable formulation, the Wegovy pill carries a boxed warning regarding the risk of thyroid C-cell tumors observed in rodent studies, for which human relevance remains undetermined.

The medication is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and the label notes that routine calcitonin testing is of uncertain clinical value. Other warnings and precautions named in the prescribing information include pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury from volume depletion, severe gastrointestinal reactions, diabetic retinopathy complications, elevated heart rate, and pulmonary aspiration during anesthesia. When co-administered with levothyroxine, oral semaglutide increased total thyroxine exposure (area under the curve) by 33%, making this a reason to raise the combination with a prescriber.

No clinically significant pharmacokinetic interactions were observed with medications including metformin, lisinopril, warfarin, omeprazole, digoxin, furosemide, rosuvastatin, ethinyl estradiol, or levonorgestrel. Detailed clinical trial incidence rates for systemic safety signals are covered in our guide on semaglutide side effects.

Related

Choosing an appropriate semaglutide therapy requires weighing administration formats, monthly out-of-pocket costs, and labelled safety considerations across the GLP-1 drug class. Explore our detailed breakdown in the Wegovy pill vs injection comparison, examine out-of-pocket expenses in our Wegovy pill cost analysis, review daily dosing protocols in how to take the Wegovy pill, and contrast indications in our Wegovy pill vs Rybelsus review. For broader clinical context across the drug class, see our analyses of semaglutide side effects, Ozempic vs Wegovy, and Zepbound vs Wegovy.

To evaluate whether the Wegovy pill fits your personal health profile, consult a licensed healthcare provider to review your medical history and discuss oral semaglutide therapy.

This article provides general educational information and does not constitute medical advice. Always consult a licensed healthcare professional regarding clinical diagnoses, prescription medications, and individual treatment plans.